Oxford University Press

SHERPA: Yellow

People

  1. Farooki
    Farooki
  2. Boland
    Boland
  3. Fornier
    Fornier

Groups

  1. Department of Medicine (5)
  2. Division of Subspecialty Medicine (5)
  3. Endocrinology (5)
  4. Survivorship Research (5)
  5. Breast Medicine Service (1)
  6. Orthopaedic Service (1)
  7. Solid Tumor Oncology Division (1)
  8. Surgery (1)
Search Within
  1. "Endocrinology"
  2. "Azeez Farooki"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (1)
Groups
  1. Department of Medicine (5)
  2. Division of Subspecialty Medicine (5)
  3. Endocrinology (5)
  4. Survivorship Research (5)
  5. Breast Medicine Service (1)
  6. Orthopaedic Service (1)

More Groups

People
  1. Azeez Farooki (5)
  2. Monica Fornier (1)
  3. Patrick Boland (1)
Years
  1. 2021 (1)
  2. 2020 (1)
  3. 2016 (2)
  4. 2015 (1)
Publications
  1. Annals of Oncology (5)

Results (5)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A risk analysis of alpelisib (ALP)-induced hyperglycemia (HG) using baseline factors in patients (pts) with advanced solid tumours and breast cancer (BC): A pooled analysis of X2101 and SOLAR-1
    Meeting Abstract

    Rodon, J.; Demanse, D.; Rugo, H. S.; Andre, F.; Janku, F.; Mayer, I.; Burris, H.; Simo, R.; Farooki, A.; Hu, H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • EPIK-B3: A phase III, randomised, double-blind (DB), placebo (PBO)-controlled study of alpelisib (ALP) + nab-paclitaxel (nabPTX) in advanced triple-negative breast cancer (TNBC) with either PIK3CA mutation or phosphatase and tensin homolog (PTEN) loss without PIK3CA mutation
    Meeting Abstract

    Sharma, P.; Farooki, A.; Fasching, P. A.; Loi, S.; Peterson, K.; Prat, A.; Tripathy, D.; Xu, B.; Yardley, D. A.; Mills, D.; more...
    Annals of Oncology (2020)

    Fulltext@MSK | Save
  • Phase 1b study of WNT inhibitor ipafricept (IPA, decoy receptor for WNT ligands) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
    Meeting Abstract

    Weekes, C.; Berlin, J.; Lenz, H. J.; O'Neil, B.; Messersmith, W.; Cohen, S.; Dendinger, C.; Shahda, S.; Kapoun, A.; Zhang, C.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
    Meeting Abstract

    Messersmith, W.; Cohen, S.; Shahda, S.; Lenz, H. J.; Weekes, C.; Dotan, E.; Denlinger, C.; Kapoun, B. O. A.; Kapoun, A.; Zhang, C.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Atypical femur fractures associated with use of bisphosphonates and denosumab
    Journal Article

    Farooki, A.; Fornier, M.; Boland, P.
    Annals of Oncology (2015)

    Fulltext@MSK | Save